# Equal Value of Life Years Gained

The Equal Value of Life Years Gained or evLYG is a generic measure used to determine how much a medical treatment can extend the life of the patient. Unlike other healthcare metrics, the evLYG does not consider the quality of life for the patient; it exclusively considers the length of life. It is used in economic evaluation to determine the added time a treatment may give a patient. Critics argue the evLYG measurement is flawed because it values a medication based solely on the added years of life. A higher priced drug that both improves quality of life and adds two years of life receives the same evLYG score as a lower priced drug that adds two years but does not improve quality of life.
The evLYG is used in concert with the Quality-Adjusted Life Year (QALY) to reduce the discriminatory characteristics of the QALY, which has been criticized as being ageist or ableist for placing more value on the lives of younger people without disability. The Institute for Clinical and Economic Review (ICER) uses a hybrid of the QALY and the evLYG to determine treatment prices. Critics have argued the use of the evLYG along with the QALY does not do enough to fully eliminate the discriminatory aspects of the QALY measurement.

## Calculation

The evLYG measures the cost of a treatment to prolong life for a year, without considering the quality of life of that year. All additional years of life gained from a treatment are considered to be “full health,” regardless of the state of the patient. “Full health” is defined as the average health of the population, and set at 0.851 on a 0-1 scale. In effect, this measure makes treatments appear to have a greater impact if they extend the patients life, even if the patient themselves is disabled, elderly, or terminally ill.

## Use

The evLYG is not in mainstream use, and instead remains a measuring tool advocated for by the Institute for Clinical and Economic Review. The Centers for Medicare and Medicaid Services has announced that they are considering using the evLYG metric for medicare drug price negotiations, but the decision to implement the metric has not yet been made.

## Criticism

While evLYGs were introduced to calm criticism that the QALY metric could be discriminatory, there has still been significant criticism of the evLYG metric.
Critics argue that the evLYG relies on generic Patient Reported Outcomes for specific medical cases. Specifically, that the weightings for the evLYG metric were constructed by people unfamiliar with the specific patients being measured. In other words, the metric is attempting to be a “one-size-fits-all” solution for a very diverse patient group.
Other critics argue that the evLYG metric ignores additional dimensions of value that can be provided by a specific treatment. For example, two treatments may provide the same extension of life, but one treatment might reduce the burden on the healthcare system while the other does not. These two treatments would be seen as providing the same value under the evLYG metric, despite the additional benefits provided by the latter.
Another criticism is that the evLYG metric ignores the quality of a patient’s health. Not every medical condition is life-threatening, and the evLYG metric would be useless in those cases. For example, a treatment for blindness would be considered useless under the evLYG metric, since treating blindness doesn’t directly expand the patient’s lifespan.